Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Diagnostics Oncology, Genetics and epigenetics, Laboratory management, Biochemistry and molecular biology, Omics

Tackling the Testing Challenge in Lung Cancer

At a Glance

  • New discoveries in lung cancer genetics and biomarkers have led to the need for revised molecular testing recommendations
  • Three organizations have teamed up to issue updated guidelines that include new genetic tests
  • Genes such as ROS1, ERBB2, MET, BRAF, RET, and KRAS can provide new insight into the disease and offer a pathway to investigational therapies
  • Lung cancer is a rapidly evolving field and laboratories are encouraged to review and adopt the new recommendations as soon as possible

Lung cancer remains one of the world’s most significant causes of death, with the disease accounting for approximately one-fifth of all cancer mortality worldwide. As with most cancers, it’s possible that we could reduce those numbers with the help of appropriate testing to detect lung cancer early, stratify patients by risk, and identify appropriate treatments for each patient’s unique disease. Molecular testing can help – but to take full advantage of its scope and power, we need up-to-date testing recommendations to help guide its use.

Read the full article now

Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine
Register

Or Login as a Guest or via Social Media

  1. NI Lindeman et al., “Updated molecular testing guidelines for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors”, J Thorac Oncol, 13, 323–358 (2018). PMID: 29355391.

About the Author

Neil Lindeman

Neil Lindeman is AMP Co-chair and Member, Director of Molecular Diagnostics at Brigham and Women’s Hospital, and Associate Professor of Professor of Pathology at Harvard Medical School in Boston, USA.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register